Given that endocannabinoid lipid tone (2-AG and AEA) and CB1R expression were reduced on Day 7 and that AEA was increased over controls on Day 42 of formoterol-induced headache (Fig. 4), the next study asked if normalizing eCB tone using pharmacological inhibitors of 2-AG degradation, MAGL (MJN) and AEA degradation, FAAH (JNJ) or a non-selective CB1/CB2R agonist (WIN55,212-2), could mitigate the behaviors at these time points after a single bolus. The gene discussed is MGLL; the disease is Headache.